Back لقاح المكورات الرئوية المقترن Arabic Vacuna antineumocócica conjugada Spanish ന്യുമോകോക്കൽ കോൺജുഗേറ്റ് വാക്സിൻ Malayalam Vacina pneumocócica conjugada Portuguese วัคซีนนิวโมคอคคัสชนิดคอนจูเกต Thai Pneumococcal conjugate vaccine TW

Pneumococcal conjugate vaccine

Pneumococcal conjugate vaccine
Prevenar 13
Vaccine description
TargetStreptococcus pneumoniae
Vaccine typeConjugate
Clinical data
Trade namesPrevnar 20, Prevnar 13, Synflorix, others; discontinued Prevnar (PCV7)
Other namesPCV, pneumococcal vaccine, capsular polysaccharides[1]
AHFS/Drugs.comMonograph
MedlinePlusa607021
License data
Pregnancy
category
Routes of
administration		Intramuscular
ATC code
Legal status
Legal status
Identifiers
ChemSpider
  • none
KEGG

Pneumococcal conjugate vaccine is a pneumococcal vaccine made with the conjugate vaccine method and used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine. The World Health Organization (WHO) recommends the use of the conjugate vaccine in routine immunizations given to children.[18][19]

Vaccine-mediated immunity is "conferred mainly by opsonophagocytic killing of S. pneumoniae."[20]

The most common side effects in children are decreased appetite, fever (only very common in children aged six weeks to five years), irritability, reactions at the site of injection (reddening or hardening of the skin, swelling, pain or tenderness), somnolence (sleepiness) and poor quality sleep.[13][20] In adults and the elderly, the most common side effects are decreased appetite, headaches, diarrhea, fever (only very common in adults aged 18 to 29 years), vomiting (only very common in adults aged 18 to 49 years), rash, reactions at the site of injection, limitation of arm movement, arthralgia and myalgia (joint and muscle pain), chills and fatigue.[13][20]

  1. ^ a b "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration. 21 December 2022. Archived from the original on 3 April 2022. Retrieved 2 January 2023.
  2. ^ a b "Vaxneuvance APMDS". Therapeutic Goods Administration. 24 January 2022. Archived from the original on 5 February 2022. Retrieved 5 February 2022.
  3. ^ a b "Prevenar 20". Therapeutics Goods Administration, The Department of Health and Aged Care. The Australian Government. Archived from the original on 5 January 2023.
  4. ^ "Prevenar 20 (Pfizer Australia Pty Ltd)". Therapeutic Goods Administration. 13 January 2023. Archived from the original on 27 March 2023. Retrieved 9 April 2023.
  5. ^ "Summary Basis of Decision (SBD) for Vaxneuvance". Health Canada. 25 February 2022. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
  6. ^ "Summary Basis of Decision - Prevnar 20". Health Canada. 31 August 2022. Archived from the original on 29 September 2022. Retrieved 22 September 2022.
  7. ^ "Regulatory Decision Summary for Capvaxive". Drug and Health Products Portal. 15 July 2024. Retrieved 27 December 2024.
  8. ^ "Summary Basis of Decision for Capvaxive". Drug and Health Products Portal. 16 December 2024. Retrieved 25 January 2025.
  9. ^ Cite error: The named reference Prevnar 13 FDA label was invoked but never defined (see the help page).
  10. ^ "Prevnar 20- pneumococcal 20-valent conjugate vaccine injection, suspension". DailyMed. Archived from the original on 21 August 2021. Retrieved 20 August 2021.
  11. ^ "Vaxneuvance- pneumococcal 15-valent conjugate vaccine crm197 protein adsorbed injection, suspension". DailyMed. Archived from the original on 21 August 2021. Retrieved 20 August 2021.
  12. ^ "Capvaxive- pneumococcal 21-valent conjugate vaccine injection, solution". DailyMed. 17 June 2024. Retrieved 5 September 2024.
  13. ^ a b c Cite error: The named reference Prevenar 13 EPAR was invoked but never defined (see the help page).
  14. ^ Cite error: The named reference Synflorix EPAR was invoked but never defined (see the help page).
  15. ^ Cite error: The named reference Vaxneuvance EPAR was invoked but never defined (see the help page).
  16. ^ Cite error: The named reference Vaxneuvance EU was invoked but never defined (see the help page).
  17. ^ Cite error: The named reference Apexxnar EPAR was invoked but never defined (see the help page).
  18. ^ World Health Organization (2019). "Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper –February 2019". Wkly Epidemiol Rec. 94 (8): 85–104. hdl:10665/310970.
  19. ^ "Summary of WHO Position Paper on Pneumococcal conjugate vaccines in infants and children under 5 years of age, February 2019" (PDF). World Health Organization (WHO). 21 April 2019. Archived from the original (PDF) on 8 March 2022.
  20. ^ a b c "Prevnar 20 – pneumococcal 20-valent conjugate vaccine injection, suspension: Wyeth Pharmaceutical Division of Wyeth Holdings LLC". Philadelphia, Pennsylvania: Wyeth Pharmaceuticals, LLC (A subsidiary of Pfizer Incorporated). June 2021. p. 11. Archived from the original on 5 September 2022. Retrieved 9 August 2022.

Pneumococcal conjugate vaccine

Dodaje.pl - Ogłoszenia lokalne